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Abstract
Concern has been raised about the presence of toxicants in
electronic cigarette (EC) aerosol, particularly carbonyl com-
pounds (e.g., acrolein) that can be produced by heating glycerol
and glycols used in e-liquids. We investigated exposure to carbon
monoxide (CO), nicotine (by measuring cotinine in urine), and
to acrolein (by measuring its primary metabolite, S-(3-hydroxy-
propyl)mercapturic acid (3-HPMA) in urine) before and after 4
weeks of EC (green smoke, a "cig-a-like" EC, labeled2.4%nicotine
by volume) use, in 40 smokers. Thirty-three participants were
using EC at 4 weeks after quitting, 16 (48%) were abstinent (CO-
validated) from smoking during the previous week (EC only
users), and 17 (52%) were "dual users." A signiﬁcant reduction
in CO was observed in EC-only users [–12 ppm, 95% conﬁdence
interval (CI), –16 to –7, 80% decrease) and dual users (–12 ppm,
95%CI, –19 to –6, 52% decrease). Cotinine levels also declined,
but to a lesser extent (EC-only users: –184 ng/mg creatinine; 95%
CI, –733 to –365, 17% decrease; and dual users: –976 ng/mg
creatinine; 95%CI, –1,682 to –270, 44% decrease). Mean 3-
HPMA levels had decreased at 4 weeks by 1,280 ng/mg creatinine
(95%CI, –1,699 to –861, 79% decrease) in EC-only users and by
1,474 ng/mg creatinine (95%CI, –2,101 to –847, 60% decrease)
in dual users. In dual users, EC use signiﬁcantly reduced exposure
to CO and acrolein because of a reduction in smoke intake. EC
may reduce harm even in smokers who continue to smoke, but
long-term follow-up studies are needed to conﬁrm this. Cancer Prev
Res; 8(9); 873–8. 2015 AACR.
Introduction
Cigarette smoke contains a number of carcinogens. Tobacco-
speciﬁc nitrosamines are among themost recognized, but someof
the carbonyl compounds that are formed during the combustion
process, such as formaldehyde, acetaldehyde, and acrolein, are
also considered to be carcinogenic (1).
Electronic cigarettes (EC)mayhave apotential for public health
beneﬁt, as EC use does not involve tobacco combustion, which is
the primary source of the dangerous chemicals to which smokers
of conventional cigarettes are exposed. However, heating the
liquid used in EC, which typically contains nicotine, ﬂavorings,
propylene glycol, and/or glycerine, can also result in the forma-
tion of new compounds, and previous studies found small
amounts of formaldehyde and acetaldehyde in EC cartridges and
aerosol (2). The presence of acrolein in aerosol has also been
found (3–5).
Acrolein (2-propenal) is present in cigarette smoke at levels
between 60 and 100 mg/cigarette (6). Its adverse effects are
dose- and cell type–dependent and inﬂuenced by experimental
conditions (7). Animal experiments showed that acrolein can
have a range of adverse effects, including a role in carcinogen-
esis (8, 9); excessive mucus production and macrophage and
neutrophil accumulation with consequent production of proin-
ﬂammatory cytokines and proteases (10); damage to neurons
and myelin disruption (11); and may play a role in the
progression of atherosclerosis (12) and cardiovascular disease
(13). The main pathway for elimination of acrolein is conju-
gation with glutathione (GSH) in the liver, followed by enzy-
matic cleavage of the g-glutamic acid and glycine residues,
respectively, in the liver and in the kidney and N-acetylation
of the resultant cysteine conjugate to form S-(3-oxopropyl)-N-
acetylcysteine (OPMA) in the kidney. Reduction of this alde-
hyde yields S-(3-hydroxypropyl)mercapturic acid (3-HPMA;
other name S-(3-hydroxypropyl)-N-acetylcysteine), the main
metabolite of acrolein found in urine (9).
As acrolein is found in both tobacco smoke and EC aerosol,
there is concern that people who use EC and continue to smoke
tobacco (so-called dual users) might be exposed to higher levels
than those who smoke only conventional cigarettes. To help
consider the potential for EC in harm reduction, data are needed
comparing the concentration of toxicants in smokers of conven-
tional cigarettes, users of EC, and dual users. We investigated
exposure to acrolein (asmeasured by its primarymetabolite, S-(3-
hydroxypropyl)mercapturic acid (3-HPMA; other nameN-Acetyl-
S-(3-hydroxypropyl)-L-cysteine), in urine; Fig. 1) together with
exposure to nicotine and carbon monoxide (CO) in a cohort of
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40 smokers before and after 4 weeks of EC use, both in exclusive
EC users and dual users.
Materials and Methods
Participants
Forty adult smokers wanting to stop smoking were recruited
through advertisements in free London newspapers. We excluded
women who were pregnant or breastfeeding, smokers with any
current serious illness, and thosewhohadusedEC formore than1
week in the past.
Study procedures
Participants were screened over the telephone and attended a
baseline session 1 week prior to their target quit date (TQD),
where they provided written informed consent and baseline
measures. Participants were advised to smoke ad lib for the
following week. On the TQD, participants were provided with
their EC and received instructions on its use. They were instructed
to use EC ad-lib. Two cartridges per day were supplied initially,
with the supply adjusted to actual use later. Participants received
standard withdrawal-oriented behavioral support (14) at base-
line, TQD, and at four further weekly sessions. A subsample of 10
participants also provided pharmacokinetic (PK) data on nicotine
delivery from EC. The PK part of the study is covered in a separate
report (15).
The studywas approved by theNHSHealth ResearchAuthority,
NRES Committee London (12/LO/1987) and registered on
ClinicalTrials.gov (NCT01714778).
Study product
The study used a Green Smoke EC (labeled 2.4% nicotine), a
ﬁrst-generation "cig-a-like" device, purchased directly from the
manufacturer's website. At the time of the study, the company
produced only one model. In our previous study, the model
provided a consistent nicotine content and delivered 9 mg of
nicotine in aerosol over 300 puffs (16), which was in the
middle range of the products tested. Peak mean plasma nico-
tine concentration achieved after 5 minutes of ad lib use, after
overnight abstinence, was 5.7 ng/mL (15). While many EC
include propylene glycol only, Green Smoke includes propyl-
ene glycol and vegetable glycerine, the latter being the precursor
to acrolein (17).
We tested aerosol generated from 5 Green Smoke cartridges for
acrolein content using a smokingmachine as described previously
Figure 1.
The process by which acrolein is
metabolized.
Table 1. Participant characteristics
Characteristic
Abstinent
at 4 weeks
(EC use only)
(n ¼ 16)
Smoking at
4 weeks
(dual users)
(n ¼ 17)
Age, mean (SD) 44.8 (13.22) 48.2 (12.37)
Gender: N (%) male 8 (50%) 9 (52.9%)
Cigarettes per day, mean (SD) 16.3 (8.68) 21.0 (11.87)
FTCDa, mean (SD) 3.88 (2.28) 4.65 (2.09)
Previous quit attempts, mean (SD) 2.63 (1.02) 2.29 (1.05)
In full time employment, N (%) 10 (62.5%) 11 (64.7%)
White British, N (%) 10 (62.5%) 9 (52.9%)
aFTCD ¼ Fagerstrom Test for Cigarette Dependence (33).
Volunteers responding to advertisements (N = 111)
• Participants 
ineligible or no 
longer wished to 
participate (N = 30). 
• Responded to 
advertisement after 
sample size was 
reached (N = 37)
Provided written informed consent (N = 44)
Dropped out (N = 4) before 
TQD
Set Target Quit Date (TQD) and provided baseline 
biologic samples (N = 40)
Lost to follow-up (N = 6)
Provided biologic samples at 4 weeks post TQD (N = 34)
Abstinent (N = 16) Smoking (N = 18)
Using EC 
(N = 16)
Not 
using 
EC 
(N = 0)
Using EC 
(N = 17)
Not using 
EC (N = 1)
Included in analyses of biologic samples (N = 33)
Figure 2.
The ﬂow of participants throughout the study. No smoking at all during the
last week of treatment validated with a CO reading < 10 ppm.
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(3). The average acrolein yield in aerosol delivered in 15 puffs was
19.4 ng (SD 1.5).
Measures
Demographic and smoking history data were collected at
baseline. At each visit, participants completed the Mood and
Physical Symptoms Scale (MPSS; ref. 18), a commonly used
assessment of tobaccowithdrawal symptoms and urges to smoke;
reported on their cigarette and EC use; and provided an end-
expired CO reading.
Urine samples were collected at TQD and at 4 weeks after TQD
to assay for 3-HPMA and cotinine. The urine samples were stored
at 20C before being couriered to ABS Laboratories, Ltd. (19)
who performed the assays.
The urine was assayed for 3-HPMA using an LC-MS/MS assay
developed and validated by ABS Laboratories using 3-HPMA-
D3 as the internal standard. The inter-batch precision (CV) and
accuracy results for the QC samples analyzed during the anal-
ysis of the samples from this study had precision less than or
equal to 4.9% and a mean accuracy that ranged from 93.1% to
107.1%.
The urine samples were assayed for free cotinine using an LC-
MS/MS assay over the calibration range of 1 to 1,000 ng/mL. The
inter-batch precision (CV) and accuracy results for the QC sam-
ples analyzed during the analysis of the samples from this study
hadprecision belowor equal to 9.3%and an average accuracy that
ranged from 95.8% to 102.3%.
The urinary creatinine levels were assayed in a clinical labora-
tory using the standard Jaffe's reaction.
All the analytical methods were validated, and the analysis of
the samples from this studywas performed in accordancewith the
FDA Guidance for Industry (20) and the EMA Guideline on
bioanalytical method validation (21).
Participants were asked to report any adverse events (AE) on a
weekly basis. All AEs were assessed for their seriousness, causality,
and severity in accordance with the ICH Guideline for Good
Clinical Practice (22).
Statistical considerations
In our previous study, use of conventional cigarettes was
associated with 3-HPMA levels of 1,614 ng/mL (SD ¼ 1,141),
whereas in users of EC, this was 616 ng/mL (SD ¼ 509; ref. 23).
Eleven participants would be needed to have 85% probability
of detecting this difference (P < 0.05, two-sided). We recruited
40 participants with the expectation that at the end of the 4-
week course, 10 would be lost to follow-up, 15 would be
smoking EC only, and 15 would be using both EC and con-
ventional cigarettes.
Participant characteristics were summarized with descriptive
statistics. Changes in CO, cotinine, and 3-HPMA from baseline to
4weeks after TQDwere assessed using paired sample t-test. At end
of treatment, one sample had a cotinine concentration below
limits of quantiﬁcation, and sowe used a value of LLOQ/10 in the
analysis. All samples haddetectable levels of 3-HPMA.Differences
in average change scores between participants who did and did
not smoke at all in the week prior to the follow-up testing were
examined using t-tests. For these analyses, we considered parti-
cipants to be abstinent if they reported not smoking (not even a
puff) over the previous week validated by a CO reading of <10
ppm. In reporting 4-week abstinence rates, we considered those
lost to follow-up as nonabstainers. Ta
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Results
Table 1 shows participant characteristics. Participant ﬂow is
shown in Fig. 2. Six participants were lost to follow-up, 33 were
using EC at the end of treatment, and one was not using EC
anymore. The 33 participants using EC were included in the
analyses below.
Changes inCO, urinary cotinine, and 3-HPMA levels are shown
in Table 2. Average daily EC cartridges use and number of days EC
were used in the last week of treatment are shown in Table 3.
Of participants who reported smoking at 4 weeks after TQD,
sevenhad smokedone toﬁve cigarettes in the lastweek and10had
smoked more than 5. The average CO levels for these two groups
were 7ppm(SD, 4; range, 1–15) and14ppm(SD, 8; range, 5–33),
respectively.
There was a signiﬁcant decrease in 3-HPMA levels in abstainers,
but also in participants who continued to smoke (P < 0.05). Three
participants showed an increase in 3-HPMA; one by 34% and
another by 30% which was associated with a 50% and 20%
increase in end-expired CO level, respectively, indicating an
increase in smoke intake. Another participant who also continued
to smoke had a marginal 6% increase in 3-HMPA levels accom-
panied by an 11% decrease in CO levels. All other participants
recorded a decrease in 3-HPMA levels (from 9% to 94% of
baseline).
Urinary 3-HPMA levels at 4 weeks were highly correlated with
the concentration of CO in expired breath, i.e., with the intake of
smoke from cigarettes (r ¼ 0.82; P < 0.001).
Participants who did not manage to stop smoking had signif-
icantly higher baseline cotinine (2,203vs. 1,073ng/mg creatinine,
t¼ 2.36, P¼ 0.025) and CO (23 vs. 15 ppm, t¼ 2.39, P¼ 0.023)
levels than abstainers.
Overall, 16 of the 40 participants (40%) who started treatment
achievedCO-validated abstinence in the last weekof treatment. In
addition to this, 11 nonabstainers (an additional 28%) reduced
their CO readings by at least 50% compared with baseline.
There were no serious adverse effects from EC use. Transient
mild to moderate events were recorded in 12 participants (all
recorded by a single participant unless stated otherwise) and
included chest discomfort (n ¼ 2), nausea, vomiting, dizziness,
anxiety, ﬂatulence, upper airways secretion, vertigo, oral discom-
fort (n¼ 2), dry nose, throat or mouth (n¼ 2), headache (n¼ 2),
and throat irritation.
Discussion
The headline ﬁnding concerning acrolein is that in dual users,
EC use signiﬁcantly reduces rather than increases exposure to this
toxicant. As expected, dual use also reduced smoke intake gener-
ally, as indexed by expired CO levels.
Acrolein levels of 337  383 mg/24h were reported for non-
smokers previously (N ¼ 100; ref. 24). Assuming an average
creatinine excretion rate of 1,400mg/24h, these levels correspond
to 259  295 ng/mg creatinine. This is somewhat lower than the
levels we found among ECuserswho abstained from smoking but
used EC (343  178 ng/mg), but these are still 4- to 6-fold lower
than concentrations in smokers (25). There is a similar relation-
ship between the 5-fold reduction in acrolein intake in smokers
who stopped smoking while using EC in our study and the results
of a previous study of 17 smokers abstinent for 4 weeks (and not
using EC) in whom the acrolein biomarker (HPMA) was reduced
7-fold (26).
Participants who managed to achieve complete abstinence
from smoking had lower baseline smoke intake as measured by
CO, cotinine, andHPMA than thosewho continued to smoke. No
other baseline differences between these two groups were
detected. Interestingly, in the successful abstainers, EC were used
with sufﬁcient frequency to provide accumulated cotinine levels
similar to those recorded at baseline. Participants who did not
manage to stop smoking altogether (dual users) and who started
with higher cotinine levels experienced a signiﬁcant reduction in
cotinine levels despite dual use. In fact, there was a trend for dual
users to reduce their cotinine levels more than abstainers,
although the difference between the two groups did not reach
statistical signiﬁcance (P¼ 0.072). Dual users were trying to limit
their smoking and reduced substantially their smoke intake, as
shown by the reduction in their expired CO. Although they were
vaping with the same frequency and used a similar number of
cartridges per day as abstainers, they did less well in maintaining
their high baseline cotinine levels. The inability to obtain sufﬁ-
cient nicotine levels from the relatively weak cig-a-like EC product
used in this studymayhave contributed to their inability to switch
to EC fully.
The validated quit rate observed in this study (40%) is com-
parable with that achieved by the UK Stop Smoking Services
which use a combination of behavioral support and pharmaco-
therapy (NRT, bupropion, or varenicline) and have reported over
the past 5 years validated 4-week quit rates of 31% to 37% (27).
It is interesting to note that only 15% of participants dropped
out during the ﬁrst 4 weeks of treatment, which is less than what
we normally observe in studies using traditional stop-smoking
medications. For instance, in a recently completed trial where
participants received the standard UK Stop Smoking Service
treatment with support identical to the current study, 46% of
participants dropped-out by 4 weeks (28). EC may thus improve
treatment retention compared with traditional treatments. They
may also have another potentially important attribute if patients
who do not succeed in stopping smoking continue to use EC and
reduce their toxin intake in the long term; the extent to which this
happens is currently not known.
Dual use of EC and conventional cigarettes is often cited as a
concern because of a possibility that it may expose dual users to
greater health risks than smoking alone (5). Theoretically, if
smokers are getting nicotine from an alternative "cleaner" source,
then their need for nicotine from cigarettes should decrease,
Table 3. EC use at week 4
Total sample
(n ¼ 33)
Abstinent at 4 weeks
(n ¼ 16; EC use only)
Smoking at 4 weeks
(n ¼ 17; dual users) Sig
Mean number of cartridges used/daya (SD) 1.54 (0.85) 1.51 (0.89) 1.56 (0.83) P ¼ 0.878
Mean number of days EC useda (SD) 6.24 (1.73) 6.31 (1.89) 6.18 (1.63) P ¼ 0.826
Abbreviation: Sig, statistical signiﬁcance.
aUse over the previous week at week 4.
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which in turn should generate a reduction in smoking and an
accompanying reduction in toxicant intake. In some countries,
NRT is licensed for this purpose (29). Results of this study support
ﬁndings from other cohort studies that show that EC use can help
those who do not manage to stop smoking altogether to reduce
cigarette consumption, with an accompanying decrease in bio-
markers of tobacco exposure (15, 30, 31).
The study had several limitations. Our cohort consisted of
people who wanted to stop smoking, and the results may not
generalize to smokers only interested in cutting down. We only
monitored EC use over 4 weeks—vaping behavior may change
further with time. It is possible that Green Smoke is on the lower
endof the spectrumof acroleindelivery and that other brandsmay
deliver higher levels, although all EC brands tested so far released
levels of acrolein in the aerosol at much lower levels than cigar-
ettes (3). Our study included a "cig-a-like" EC. In a recent lab
study, an advanced EC with a tank system and variable voltage
also released only very low levels of carbonyl compounds in
normal use (32), but future EC products may have different
potential for exposure. We only used biomarkers of two toxicants,
CO and acrolein, but given the signiﬁcant decrease in smoke
intake, the ﬁnding is likely to concern toxicants from cigarette
smoke generally. Finally,wedidnot includenonsmoking controls
to establish environmental acrolein exposure.
In conclusion, ECuse inboth smokerswhoquit smoking and in
dual users was accompanied by a signiﬁcant decrease in tobacco
smoke toxicant exposure.
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